MedTrace Logo

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

NCT02358473 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.

Conditions

Interventions

BIOLOGICAL

mogamulizumab

Mogamulizumab will be administered by IV infusion.

DRUG

Docetaxel

Docetaxel will be administered by IV infusion.

Sponsors & Collaborators

  • Kyowa Kirin, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Kurman · Kyowa Kirin, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02358473 on ClinicalTrials.gov